Use of PA66 as a diagnostic marker for diminished ovarian reserve function
By detecting the combination of microplastic nylon 66 (PA66) and its random forest model in the kit, the problem of difficulty in early diagnosis of ovarian reserve function in the existing technology is solved, and the accurate diagnosis of ovarian reserve function is achieved and the improvement of ovarian reserve function is improved. The accuracy of fertility assessment and the feasibility of treatment were found.
Patent Information
- Application Number
- CN202411311605.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-20
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2044-09-20
AI Technical Summary
The existing technology lacks effective methods for early diagnosis and treatment of ovarian reserve impairment, which leads to the "bottleneck problem of declining fertility is difficult to solve, and the lack of fast and efficient diagnostic kits affects the early identification and intervention of ovarian reserve impairment.
Using microplastic nylon 66 (PA66) as a biomarker, the PA66 content in the serum or follicle fluid of the subject is detected in the kit and combined with a random forest model for diagnosis, providing a non-invasive diagnostic method that is easy to detect.
It has achieved an early accurate diagnosis of ovarian reserve loss, improved the sensitivity and specificity of the diagnosis, and can identify and intervene early, improving reproductive health and quality of life.
Smart Images

Figure CN118817904B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of medical detection, and in particular, to the use of PA66 as a diagnostic marker for diminished ovarian reserve function. Background Art
[0002] Premature ovarian failure in women of childbearing age is a key cause of decreased fertility. Diminished Ovarian Reserve (DOR) refers to a decrease in the number and / or quality of oocytes, leading to insufficient ovarian function. DOR that occurs after the age of 40 is usually physiological, while women who experience DOR early in life will experience a premature decline in their reproductive function and insufficient fertility. The most common clinical manifestations of DOR are menstrual disorders, endocrine disorders, poor ovarian stimulation response, and infertility. If not treated in time, it is likely to progress to premature ovarian failure within a few years. DOR accounts for about 20% of female ovarian diseases and has an incidence rate of about 10% in the infertile population. Its incidence rate is increasing year by year, and the age of patients is showing a trend of younger age, which seriously affects the reproductive health and quality of life of a large number of women. Due to the complex etiology, hidden onset, difficulty in prevention, and lack of early screening markers, the treatment effect is limited, and it is still one of the great challenges in the clinical treatment of infertility. Therefore, how to identify and restore the ovarian function of DOR patients as early as possible and accurately target the "bottleneck problem" of declining fertility is an issue concerning human welfare that needs to be urgently addressed.
[0003] At present, DOR is mainly diagnosed by the decrease of antral follicle counting (AFC) and anti-Müllerian hormone (AMH) and the increase of serum basal follicle-stimulating hormone (FSH) level. However, there is no recognized unified diagnostic standard. The ovarian reserve function of DOR patients diagnosed by the above methods has been severely reduced, and the existing diagnostic methods cannot identify and intervene early. The above problems have made the diagnosis and treatment of DOR a hot and difficult issue of common concern in the field of gynecology and reproductive medicine. Therefore, finding an easy-to-detect non-invasive biomarker diagnostic method to predict and diagnose diminished ovarian reserve function is of great significance for the early diagnosis and intervention of diminished ovarian reserve function.
[0004] At present, there is no rapid and efficient diagnostic kit for ovarian reserve deficiency on the market, which affects the early identification and treatment of ovarian reserve deficiency. Therefore, using an easy-to-detect non-invasive substance as a diagnosis and prediction of ovarian reserve deficiency is of great significance for its early diagnosis and intervention. Summary of the invention
[0005] In order to fill the gap in the prior art, the present invention provides a use of microplastic nylon 66 (PA66) as a diagnostic marker for ovarian reserve dysfunction. The following technical solutions are specifically provided:
[0006] One aspect of the present invention provides a use of microplastic nylon 66 (PA66) as a biomarker in the preparation of a kit for diagnosing diminished ovarian reserve function.
[0007] In one embodiment, the marker of the present invention refers to a microplastic component present in a biological sample of a subject, and the subject can be a human or a mammal. The biological sample can be selected from serum or follicular fluid derived from the subject. Preferably, the biological sample is follicular fluid.
[0008] In one embodiment, the method for using the kit includes testing the subject's ovarian reserve function impairment by testing the level of markers in the subject's serum or follicular fluid.
[0009] In one embodiment, the kit comprises a standard solution of PA66 microplastics, and the PA66 content in the sample is confirmed by a quantitative curve equation:
[0010] The quantitative curve equation of PA66: y=55.433x-5.2044, R 2 =0.99,
[0011] Where x is the injection volume of the standard, in μg, and y is the corresponding integrated area / 10 4 , R 2 is the coefficient of determination, R 2 The closer the value of is to 1, the better the regression line fits the observed value; on the contrary, R 2 The smaller the value of , the worse the fit of the regression line to the observed value.
[0012] In one embodiment, the kit includes an acid digestion solvent, which is composed of nitric acid and sulfuric acid, and the volume ratio of nitric acid to sulfuric acid is 4:1-3:2. Further, the kit also includes a glass pipette and a Py-GCMS sample injection crucible.
[0013] In one embodiment, the method of using the kit is specifically to measure the level of microplastic PA66 in the follicular fluid of the subject, and input these measured values into the random forest model to obtain the score cutoff value for judgment.
[0014] In one embodiment, the method for using the above kit for diagnosing ovarian dysfunction includes the following steps: a) preparing PA66 standard solution, with injection volumes of 0.25, 0.5, 1.0, 2.0, 3.0, 4.0, and 5.0 µg, respectively. Perform Py-GCMS testing to construct a quantitative curve. b) Take a portion of the sample and concentrate it by acid digestion. After concentration, use a glass pipette to drop it into the Py-GCMS injection crucible. After the solvent in the crucible is completely evaporated, it is tested on the machine. c) Input the marker content in the sample calculated in b) into the random forest model for calculation, and judge the ovarian reserve dysfunction of the subject according to the score.
[0015] In one embodiment, the random forest model used in the present invention can be software available on the market, which can also be optionally used as a part of the above-mentioned kit. As a preferred embodiment, the software package is used as a part of the kit. BRIEF DESCRIPTION OF THE DRAWINGS
[0016] The accompanying drawings are used to provide a further understanding of the present invention and constitute a part of the specification. Together with the embodiments of the present invention, they are used to explain the present invention and do not constitute a limitation of the present invention. In the accompanying drawings:
[0017] Figure 1 The correlation between microplastics and DOR;
[0018] Figure 2 To investigate the changes in ovarian hormones after 6 weeks of exposure to 60 mg / kg body weight microplastics using a mouse animal model;
[0019] Figure 3 Receiver operating characteristic curve (ROC) and area under the curve (AUC). DETAILED DESCRIPTION
[0020] The preferred embodiments of the present invention are described below in conjunction with the accompanying drawings. It should be understood that the preferred embodiments described herein are only used to illustrate and explain the present invention, and are not used to limit the present invention.
[0021] Example 1 Screening of differential biomarkers
[0022] The experimental samples in this invention were approved by the local ethics committee and informed consent was obtained from all subjects. A total of 70 subjects were enrolled in strict accordance with the inclusion criteria, and the content of microplastic PA66 in follicular fluid specimens of 35 patients with normal ovarian reserve (NOR) and 35 patients with confirmed diminished ovarian reserve (DOR) was detected using pyrolysis gas chromatography-mass spectrometry (Py-GCMS) technology. The basic characteristics are shown in Table 1.
[0023] Inclusion criteria: (1) women of childbearing age aged 20 to 40 years; (2) AMH < 1.1 ng / ml, bilateral ovarian AFC < 5-7, basal FSH ≥ 10 IU / L, and at least 2 of the 3 criteria were met; (3) patients with complete clinical and IVF cycle information.
[0024] Exclusion criteria: (1) women who are pregnant or lactating; (2) one of the spouses has chromosomal abnormalities; (3) a history of ovarian disease or surgery, such as ovarian endometriosis cyst, ovarian tumor, ovarian drilling, or ovarian cyst or tumor resection.
[0025] Table 1. Basic characteristics of the included population
[0026]
[0027] The detection method is as follows:
[0028] 1. Follicular Fluid Collection
[0029] On the day of oocyte retrieval in patients undergoing assisted reproductive technology treatment, follicular fluid from dominant follicles containing oocytes (diameter >1.4 cm) was collected from DOR patients and NOR patients, separated, and stored at −80°C until use.
[0030] 2. Detection of microplastics (MPs) in follicular fluid samples
[0031] Sample preparation: slowly thaw the follicular fluid sample at 4°C, take 0.3-0.5g of the sample, add nitric acid to digest at 110°C and concentrate. After treatment, concentrate the treated solution to 0.5-0.7g, take 0.03-0.05g of the concentrated solution and drop it into the injection crucible for testing (after conversion, the sample injection mass is 0.02-0.04g).
[0032] Analytical instrument test: Pyrolysis gas chromatography mass spectrometry (Py-GCMS)
[0033] Test conditions: GC-MS model: GCMS-QP2020 Shimadzu; pyrolysis device: PY-3030D Frontier; pyrolysis temperature: 550PC; split ratio: 5:1; carrier gas: helium; chromatographic column: Rtx-5MS (30m*0.25mm*0.25um); heating program: 40°C for 2 min, heating to 320°C at a rate of 20°C / min, holding for 14 min, total program time 30 min. Ion source temperature: 230PC; m / z scanning range: 29-600.
[0034] The test results are as follows:
[0035] Microplastics (MPs) were detected in follicular fluid samples, among which polystyrene (PS), polyhexamethylene adipamide (PA66) and polyvinyl chloride (PVC) were the most common. Figure 1 Shows estimates of DOR (which could be an estimate of the diagnostic odds ratio or other relevant ratio) for three different materials (PS51, PVC, PA66) at the Zlog level of microplastics (MPs). Each subplot represents a material, with the horizontal axis being the standardized logarithmic level of microplastics (Zlog level of MPs) and the vertical axis being the estimate of DOR. Figure 1 It can be seen that PA66 is significantly positively correlated with DOR ( Figure 1 ). The results suggest that microplastics can affect the female reproductive system and ovarian function, thereby affecting female fertility. The PA66 content may serve as an important marker for ovarian dysfunction.
[0036] Furthermore, we used a mouse model to verify the effect of PA66 on animal ovarian function:
[0037] Healthy 8-week-old C57 mice were selected to ensure that the animals were of the same source and had not undergone any genetic or drug treatment. Prepare microplastic PA66 suspension. First, the high-purity PA66 microplastic powder was accurately weighed at a dose of 60 mg / kg body weight. Ultrapure water was used as the medium, and ultrasonic vibration was used to fully disperse the microplastics to form a uniform suspension. The mice were randomly divided into an experimental group and a control group, and the control group was also gavaged with an equal volume of ultrapure water. The gavage operation lasted for 6 weeks, during which the normal feeding conditions of the mice were maintained, including appropriate feed, water, and environmental temperature and humidity control. After the experiment, the ovarian function of the mice was evaluated by histological examination and hormone level determination. The orbital blood of the mice was taken to detect the levels of sex hormones, such as estradial (E2), anti-Müllerian hormone (AMH), follicle-stimulating hormone (FSH), etc., to evaluate the changes in ovarian endocrine function.
[0038] The experimental results are as follows Figure 2 As shown, after 6 weeks of exposure to 60 mg / kg body weight of microplastics in a mouse animal model, ovarian endocrine dysfunction and obvious ovarian dysfunction occurred, and hormone levels changed significantly, indicating that PA66 is closely related to ovarian function.
[0039] Example 2 Evaluation of the efficacy of PA66 as a biomarker for predicting DOR
[0040] The risk of DOR was predicted based on the concentration of PA66 in follicular fluid. The receiver operating characteristic curve (ROC) and area under the curve (AUC) were shown in Figure 2 Figure 3 As shown in the figure, the AUC of this model was 0.827 (95%CI:0.723-0.933). When the PA66 cutoff value was 0.4ug / mL, the best prediction was achieved, with a sensitivity of 74.3% and a specificity of 87.5%.
[0041] In order to verify the effectiveness of PA66 as a biomarker for detecting diminished ovarian reserve, we re-enrolled 21 healthy controls and 21 patients with diminished ovarian reserve (as a validation set, from Peking University Third Hospital, all of whom had signed informed consent), analyzed the samples of the patients in the validation set using the method and model described in Example 1 above, and compared the analysis results with the diagnosis results of clinical experts:
[0042] Table 2. Comparison of PA66 levels in patients' follicular fluid and diagnostic results
[0043]
[0044]
[0045] From the above results, it can be seen that the use of PA66 as a biomarker for the diagnosis of ovarian reserve function decline is relatively accurate, with a consistency of more than 90.47% with expert judgment.
[0046] Obviously, those skilled in the art can make various changes and modifications to the present invention without departing from the spirit and scope of the present invention. Thus, if these modifications and variations of the present invention fall within the scope of the claims of the present invention and their equivalents, the present invention is also intended to include these modifications and variations.
Claims
1. A use of PA66 as a biomarker in the preparation of a kit for diagnosing diminished ovarian reserve function, characterized in that: The PA66 refers to the microplastic nylon 66 component present in the serum or follicular fluid samples of the subjects.
2. The use according to claim 1, characterized in that The subject is a mammal.
3. The use according to claim 1, characterized in that The subjects are humans.
4. The use according to any one of claims 1 to 3, characterized in that: The method for using the kit includes testing whether the ovarian reserve function of the subject is reduced by testing the level of PA66 in the serum or follicular fluid of the subject.
5. The use according to any one of claims 1 to 3, characterized in that: The kit contains a standard solution of PA66 microplastics, and the PA66 content in the sample is confirmed by the quantitative curve equation: The quantitative curve equation of PA66 is: y=55.433x-5.2044, R 2 =0.99, Where x is the injection volume of the standard, in μg, and y is the corresponding integrated area / 10 4 , R 2 is the goodness of fit.
6. The use according to claim 5, characterized in that The kit further comprises an acid digestion solvent, which consists of nitric acid and sulfuric acid.
7. The use according to claim 6, characterized in that The volume ratio of nitric acid to sulfuric acid is 4:1-3:
2.
8. The use according to claim 6 or 7, characterized in that The kit also includes a glass pipette and a pyrolysis gas chromatography-mass spectrometer Py-GCMS injection crucible.
9. The use according to claim 8, characterized in that The kit also includes a software package for computer calculations.
10. The use according to claim 1, characterized in that The specific method of using the kit is to measure the level of microplastic PA66 in the follicular fluid of the subject, and input these measured values into the random forest model to obtain the score cutoff value for judgment.
11. The use according to claim 10, characterized in that The method for using the kit for diagnosing ovarian dysfunction comprises the following steps: a) preparing PA66 standard solution, with the injection amount being 0.25, 0.5, 1.0, 2.0, 3.0, 4.0, and 5.0 µg respectively, and performing a test on a pyrolysis gas chromatography-mass spectrometer Py-GCMS, thereby constructing a quantitative curve; b) taking a portion of the sample and concentrating it by an acid digestion method, and after concentration, dripping it into the injection crucible of the pyrolysis gas chromatography-mass spectrometer Py-GCMS using a glass pipette, and performing an on-machine test after the solvent in the crucible is completely volatilized; c) inputting the PA66 biomarker content in the sample calculated in b) into a random forest model for calculation, and judging the ovarian reserve dysfunction of the subject according to the score.
Citation Information
Patent Citations
Biomarker and kit for diagnosing hypoovarian reserve function and use method of biomarker and kit
CN118033008A
Female fertility test
US20100311188A1
